INDUCE-seq™
INDUCE-seq™ is a scalable platform technology for mapping and characterizing DNA breaks. It leverages a novel PCR-free methodology for in situ break capture and sequencing by NGS, revealing the breaks induced by any nuclease-based genome editing system with high precision.
INDUCE-seq was built from the ground up to address a key unmet need in the accurate and rapid measurement of off-targets induced by gene editing. It is the first unbiased cell-based solution that is free from PCR induced biases that distort measurements, has broad compatibility with a wide range of therapeutically relevant cells, and applicable to any nuclease-based gene editing system. INDUCE-seq provides data-driven and actionable insights to accelerate research & development, pre-clinical and clinical stages gene editing programs.
Why INDUCE-seq?
- Whole genome, cell-based assay detecting on- and off-target double strand breaks induced by gene editing
- Unbiased (PCR-free) assay producing reproducible and accurate results
- Broad compatibility with any nuclease and a range of cell inputs, (adherent or suspension cells, iPSCs, primary cells, tissue)
- Scalable workflow built for automation
Gene Editing Applications
- Off-target assessment (specificity)
- On–target mechanism
- Kinetic analysis of nuclease/editing system
- Guide contamination screening
- Nuclease development
- Optimization of editing strategy (delivery, cell model, editing modality, modifying DNA repair, HDR)
How INDUCE-seq works
How to work with us
Broken String Biosciences is the leader in combining cutting-edge PCR-free next-generation sequencing (NGS) technology, expert bioinformatics, and deep expertise in DNA damage and repair to reveal the impacts of gene editing on the genome. Our INDUCE-seq platform eliminates amplification bias allowing us to quantitatively map induced and endogenously formed breaks in the genome in all cell types and editing systems. This information is critical to develop safe and effective gene editing therapies.
Partner with Broken String Biosciences during therapeutic development to:
- Optimize your editing strategy and reduce risks in your editing system created by off- targets.
- Better understand the mechanism of your novel nuclease.
- Determine your on-target mechanism.
- Profile the editing kinetics of your system.
- Prioritize a lead candidate based on off-target risk assessment.
- Develop a comprehensive package required for IND filing.
Interested in partnering with Broken String Biosciences?
Contact us at: partnerships@brokenstringbio.com to explore partnership opportunities.